Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft modelsPaul R. Gavine, Q. May Wang|Molecular Oncology|2014Cited by 120
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive CancersKarine Smans, Paul R. Gavine|Molecular Cancer Therapeutics|2026Cited by 0